Insulet Corp (PODD)
166.19
+2.02
(+1.23%)
USD |
NASDAQ |
Apr 26, 16:00
166.27
+0.08
(+0.05%)
After-Hours: 20:00
Insulet Research and Development Expense (Quarterly): 42.00M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 42.00M |
| September 30, 2023 | 57.80M |
| June 30, 2023 | 55.10M |
| March 31, 2023 | 50.10M |
| December 31, 2022 | 49.50M |
| September 30, 2022 | 45.00M |
| June 30, 2022 | 42.60M |
| March 31, 2022 | 43.10M |
| December 31, 2021 | 41.80M |
| September 30, 2021 | 37.50M |
| June 30, 2021 | 40.10M |
| March 31, 2021 | 40.70M |
| December 31, 2020 | 38.30M |
| September 30, 2020 | 38.80M |
| June 30, 2020 | 34.20M |
| March 31, 2020 | 35.50M |
| December 31, 2019 | 35.50M |
| September 30, 2019 | 31.30M |
| June 30, 2019 | 33.00M |
| March 31, 2019 | 32.50M |
| December 31, 2018 | 33.40M |
| September 30, 2018 | 22.34M |
| June 30, 2018 | 18.80M |
| March 31, 2018 | 20.27M |
| December 31, 2017 | 20.03M |
| Date | Value |
|---|---|
| September 30, 2017 | 20.14M |
| June 30, 2017 | 18.03M |
| March 31, 2017 | 17.50M |
| December 31, 2016 | 16.03M |
| September 30, 2016 | 13.73M |
| June 30, 2016 | 12.95M |
| March 31, 2016 | 12.99M |
| December 31, 2015 | 12.90M |
| September 30, 2015 | 10.04M |
| June 30, 2015 | 12.07M |
| March 31, 2015 | 8.207M |
| December 31, 2014 | 7.286M |
| September 30, 2014 | 7.158M |
| June 30, 2014 | 6.677M |
| March 31, 2014 | 6.779M |
| December 31, 2013 | 6.424M |
| September 30, 2013 | 5.771M |
| June 30, 2013 | 5.174M |
| March 31, 2013 | 4.396M |
| December 31, 2012 | 5.847M |
| September 30, 2012 | 6.559M |
| June 30, 2012 | 6.521M |
| March 31, 2012 | 5.432M |
| December 31, 2011 | 5.804M |
| September 30, 2011 | 4.638M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
31.30M
Minimum
Sep 2019
57.80M
Maximum
Sep 2023
41.68M
Average
40.70M
Median
Mar 2021
Research and Development Expense (Quarterly) Benchmarks
| Abbott Laboratories | 684.00M |
| Stryker Corp | 350.00M |
| Becton Dickinson & Co | 290.00M |
| Haemonetics Corp | 13.26M |
| Tandem Diabetes Care Inc | 42.60M |